Indalo Therapeutics, Inc. — Form D
Indalo Therapeutics, Inc. of ST. LOUIS, MO, a company, filed a Form D exempt-offering notice with the SEC on 2017-08-01. The offering totals $26.0M, of which $9.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2017-08-01
- Form: D
- Accession: 0001654706-17-000003
- Industry: Pharmaceuticals
- Exemptions: 06c
- Total offering: $26.0M
- Amount sold: $9.0M
- Remaining: $17.0M
- Investors: 6
- Date of first sale: 2017-06-30
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-291882
Issuer
- Name: Indalo Therapeutics, Inc.
- CIK: 0001654706
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2014
- Address: 4320 FOREST PARK AVENUE, ST. LOUIS, MO, 63108
- Phone: 314-932-4032
Officers, directors & promoters (16)
| Name | Role | Location |
|---|
| Ben H Auspitz | Director | St. Louis, MO |
| Peter H Barrett | Director | St. Louis, MO |
| Rajesh H Devraj | Director | St. Louis, MO |
| George H Capps II | Executive Officer | St. Louis, MO |
| Scott H Seiwert | Executive Officer | St. Louis, MO |
| Bradford H Williamson | Executive Officer | St. Louis, MO |
| George H Capps II | Promoter | St. Louis, MO |
| Charles Bolten | Director | St. Louis, MO |
| Robert W Karr | Director | SAINT LOUIS, MO |
| Robert W Karr | Executive Officer | SAINT LOUIS, MO |
| George H Capps, II | Executive Officer | St. Louis, MO |
| Michael A Yeadon | Director | St. Louis, MO |
| David W Griggs | Director | St. Louis, MO |
| Thomas P Cirrito | Director | St. Louis, MO |
| Rajesh P Devraj | Director | St. Louis, MO |
| Michael W Yeadon | Director | St. Louis, MO |
Other filings by this issuer (2)
More